Bristol-Myers Squibb: Home
 
Investigational Compound News


Learn more about Bristol-Myers Squibb’s research and development efforts and track the progress of investigational compounds in the news. Our pipeline is one of the most innovative in the industry.

We will post periodic updates about select Phase 1 and 2 investigational compounds on this page, as new data are presented or published.


Recent Updates

Hepatitis C

Pipeline Asset Update for Daclatasvir (DCV; BMS-790052)
Discovered by Bristol-Myers Squibb through a genomics approach, daclatasvir, also known as BMS-790052 or DCV, is the first NS5A replication complex inhibitor to be investigated in hepatitis C clinical trials.
Conference on Retroviruses and Opportunistic Infections (CROI), 2012

HIV

BMS-663068 (attachment inhibitor)
Conference on Retroviruses and Opportunistic Infections (CROI), 2011
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection

To receive notifications when updates to this page are available, media and investors can sign for our “Investigational Compound News” RSS feed.

RSS Button Get RSS News Alerts

 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.
You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.